Psilocybin Causes ‘Significant Reduction’ in Symptoms of Depression, Largest of its Kind Study Shows

Psilocybin Causes ‘Significant Reduction’ in Symptoms of Depression, Largest of its Kind Study Shows
High Times

At the American Psychiatric Association (APA) 2022 Annual Meeting that began on May 21 in New Orleans, Louisiana, COMPASS Pathways unveiled the “largest randomized, controlled, double-blind study of psilocybin therapy ever completed,” according to a May 24 press release, and the data shows “significant” improvements to treatment-resistant depression (TRD) symptoms. Participants were given a single dose of investigational COMP360 psilocybin, in doses of 25 mg or 10 mg, compared to 1 mg in patients with TRD. For the study, 233 patients with TRD received either 1 mg, 10 mg, or 25 mg COMP360 psilocybin, along with psychological support from therapists. Symptoms of depression were calculated using the Montgomery-Åsberg depression rating scale (MADRS). The MADRS system has been used in the world of psychiatry since 1979 and measures apparent sadness (despondency, gloom), reported sadness, inner tension (discomfort, turmoil, dread), reduced sleep, reduced appetite, and concentration difficulty, typically in a ten-item questionnaire. The people who received a 25 mg dose of COMP360 psilocybin with psychological support experienced a “highly statistically significant reduction in symptoms of depression after three weeks.” The difference between the group that received 25 mg and the group that received 1 mg was -6.6 on the MADRS depression scale at week three. The effects also lasted very long—for three months, in some cases. The findings show that psilocybin provides “a rapid and durable response for up to 12 weeks.” Twice the number of patients who received 25 mg (20.3%) had a “sustained response” at week 12, versus those who received 1 mg (10.1%). Tolerability and adverse effects were both reported mostly favorably, despite some reports commonly seen in people with TRD such as self-injury, but it was typically over a month after treatment.

“Treatment-resistant depression is one of the biggest challenges we face in psychiatry, and chances…

Excerpt only …
READ MORE BELOW
Source : Psilocybin Causes ‘Significant Reduction’ in Symptoms of Depression, Largest of its Kind Study Shows

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.